As we age, our minds and bodies degenerate. Older people suffer pain, can't enjoy the activities they used to, forget things, and aren't as sharp mentally as younger people. But what if it were possible to slow this general decline and improve the quality of life for the aging? We would live in a happier and more productive society.
In recent years, QB3 has increasingly focused on aging-related disease. We've brought scientists together from Bay Area universities and the private sector. We want to spark productive collaborations that lead to understanding the process of aging and, ultimately, solutions to help all of us. This October, we've invited key players in the field to join us at an afternoon symposium at UCSF Mission Bay.
If you would like to learn about new research, meet leading scientists, connect to investors, and be a part of an exciting group that identifies and tackles one of the most important problems facing us today, please attend this symposium. Space is limited!
1:00 - 1:15 PM Registration
1:15 - 1:20 PM Reg Kelly (QB3): Introduction
Session I: Recent developments in understanding aging suggest that anti-aging therapies are on the horizon.
1:20 - 1:50 PM Eric Verdin (Buck Institute): "Therapy and Diagnostic Development at the Buck Institute"
1:50 - 2:10 PM Tony Wyss-Coray (Stanford): "Aging Factors in the Blood"
2:10 - 2:30 PM Susanna Rosi (UCSF): "Stress-Induced Acceleration of the Aging Process"
2:30 - 3:00 PM Coffee Break
Session II: To bring theory into practice we need biomarkers to predict disease, quantify disease progression and stratify age-related diseases.
3:00 - 3:20 PM Ron Kohanski (National Institute on Aging): "Biomarker Research"
3:20 - 3:35 PM Ben Kamens (Spring Discovery): "Applying AI Techniques to Data Analysis of Aging Biomarkers"
3:35 - 3:50 PM Kimberly Scearce-Levie (Denali Therapeutics): "Neurofilament as a Clinical Biomarker of Progression and Response"
3:50 - 4:05 PM Eric Morgen (BIOAGE): "From Longevity Biomarkers to Drug Targets"
Session III: We need to decide on the next steps to be taken for aging biomarkers.
4:05 - 5:15 PM Panel discussion: Supporting biomarker development for aging-related diseases. Moderator: Joe Betts-LaCroix (Vium)
Laura Deming (Longevity Fund)
Chris Haskell (Bayer)
Ron Kohanski (NIA)
John Newman (UCSF & Buck)
James Peyer (Apollo Ventures)
5:15 - 5:30 PM Reg Kelly: Closing Remarks
5:30 - 7:00 PM Reception